Taipei Exchange - Delayed Quote TWD

BRIM Biotechnology, Inc. (6885.TWO)

32.45 -0.95 (-2.84%)
At close: April 26 at 2:59 PM GMT+8
Key Events
Advanced Chart
Loading Chart for 6885.TWO
DELL
  • Previous Close 33.40
  • Open 33.45
  • Bid 32.45 x --
  • Ask 32.75 x --
  • Day's Range 32.30 - 33.85
  • 52 Week Range 24.60 - 84.89
  • Volume 625,477
  • Avg. Volume 1,258,917
  • Market Cap (intraday) 3.756B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -6.84
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

BRIM Biotechnology, Inc., a clinical-stage company, engages in the development of novel regenerative therapies to combat and cure ophthalmology and degenerative joint diseases. The company's lead product candidate is BRM 421, a topical ophthalmic solution for patients with moderate-to-severe dry eye syndrome that has completed a phase 2 clinical trial in the United States. It is also developing BRM 423 to treat severe corneal damage, which is in phase 1 clinical trial; BRM 424 for the treatment of neurotrophic keratitis, which is in phase 1 clinical trial; and BRM 521 to relieve and repair tissue damage caused by osteoarthritis. The company was founded in 2013 and is based in Taipei, Taiwan.

www.brimbiotech.com

--

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

More about BRIM Biotechnology, Inc.

Related News

View More
View More

Performance Overview: 6885.TWO

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

6885.TWO
9.44%
TSEC weighted index
12.21%

1-Year Return

6885.TWO
55.55%
TSEC weighted index
30.90%

3-Year Return

6885.TWO
--
TSEC weighted index
31.48%

5-Year Return

6885.TWO
--
TSEC weighted index
31.48%

Compare To: 6885.TWO

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

6885.TWO
BRIM Biotechnology, Inc.
32.45
-2.84%
Mkt Cap TWD 3.756B
Industry Biotechnology
BMRN
BioMarin Pharmaceutical Inc.
80.91
-1.53%
Mkt Cap 15.355B
Industry Biotechnology

Statistics: 6885.TWO

View More

Valuation Measures

Annual
As of 4/26/2024

  • Market Cap

    3.78B

  • Enterprise Value

    2.09B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    41.99k

  • Price/Book (mrq)

    2.18

  • Enterprise Value/Revenue

    23.19k

  • Enterprise Value/EBITDA

    -3.06

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -31.92%

  • Return on Equity (ttm)

    -51.90%

  • Revenue (ttm)

    90k

  • Net Income Avi to Common (ttm)

    -688.02M

  • Diluted EPS (ttm)

    -6.84

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.7B

  • Total Debt/Equity (mrq)

    0.21%

  • Levered Free Cash Flow (ttm)

    -371.06M

View More

Company Insights: 6885.TWO